Immunology
Century secures $60m in stock sale and buys preclinical cell therapy biotech
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and…
Eliem Therapeutics agrees to acquire Tenet
US-based Eliem Therapeutics has announced a definitive agreement for the acquisition of development-stage private biotechnology company Tenet Medicines. The acquisition…
Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase
Vertex Pharmaceuticals has agreed to acquire biotech Alpine Immune Sciences for $4.9bn, joining the growing number of pharma spending big on…
FDA grants approval for Alexion’s NMOSD treatment
The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4…
AbbVie signs agreement to acquire Landos Biopharma for $212.5m
AbbVie has entered a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5m. The strategic acquisition boosts AbbVie's…
Mirador launches with $400m to develop precision therapies
Mirador Therapeutics has announced its launch after securing more than $400m from leading life sciences investors. The US-based company will…
Capstan secures $175m Series B funds for CAR-T therapy
Capstan Therapeutics has secured $175m oversubscribed Series B financing to advance its lead in vivo chimeric antigen receptor T cell…
Alumis secures $259m to develop therapies for immune dysfunction
Alumis has secured $259m in a Series C funding round to progress the development of its clinical-stage pipeline of oral…
Shifting the paradigm – novel approaches to amyotrophic lateral sclerosis therapy
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a swiftly advancing, fatal neurodegenerative condition marked by muscle…
AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront
AbbVie has signed a partnership and licensing agreement with OSE Immunotherapeutics for the latter’s monoclonal antibody OSE-230 in a deal…
